AlphAIAlphAI — Financial news for AI agents
rttnews.comNOV 32 min read

Lonza Group To Buy Merck's CDMO Business

Lonza Group agreed to buy five U.S. CDMO sites from Merck KGaA for low-to-mid-triple-digit million Swiss francs, payable in cash. The deal, expected to close in mid-2027, will expand Lonza's U.S. footprint and add capabilities in antibody-drug conjugates and gene therapies. The acquired sites are projected to generate CHF 250 million in sales in 2028.

Original reporting
rttnews.com
Published Nov 3, 2026, 8:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 8:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lonza Group To Buy Merck's CDMO Business — source image
Source · rttnews.com
Decision brief

The 30-second read

High
01

Why it matters

The transaction is expected to close in mid‑2027 and adds CHF 250 million of projected 2028 sales, indicating a strategic move into high‑growth biopharma segments.

02

Market read

First‑report M&A in the CDMO space with material financial scale, likely influencing sector valuations and investor sentiment.

03

What to watch

Regulatory approvals for the transfer of GMP‑qualified facilities and integration risks may delay expected benefits.

Relevance 9/10Novelty 9/10Timing: today

Background

Lonza Group, a Swiss contract development and manufacturing organization, is expanding its U.S. footprint through an acquisition from Merck KGaA, a German pharmaceutical company.

Market effects

Sector

Strengthens the CDMO sector outlook as demand for antibody‑drug conjugates and gene‑therapy manufacturing rises.

Regional

Boosts the U.S. biotech manufacturing landscape, potentially attracting more investment to the region.

Global

Highlights consolidation trends in the global biopharma contract manufacturing market.

Counterpoint

What could challenge this read

The deal could overpay for assets in a competitive CDMO market, leading to margin pressure for Lonza.

Key entities

  • Company
    Lonza Group

    Swiss CDMO expanding U.S. operations.

  • Company
    Merck KGaA

    German pharma firm divesting U.S. CDMO sites.

Read at source← All news

StoryLonza to acquire Merck KGaA’s five U.S. CDMO sites

Also covered by

6 outlets

Related articles

NOV 3
HighAI 8/10

Lonza buys 5 sites from Germany’s Merck to more than double US footprint

Lonza agreed to buy five U.S. manufacturing sites from Merck KGaA for 100-600 million Swiss francs, expanding its U.S. footprint to nine sites. The deal, expected to close mid-2024, adds 1,100 employees and is projected to generate 250 million francs in annual sales by 2028. Lonza gains cancer and gene therapy production capabilities, while Merck focuses on drug development.

investing.com2 min
NOV 3
MedAI 8/10

Merck KgaA divests US CDMO business to Lonza

Merck KGaA is selling its US contract development and manufacturing organization (CDMO) business to Lonza for an estimated low- to mid-triple-digit million Swiss francs. The deal includes five US sites and around 1,100 employees, expected to close mid-2024. Lonza anticipates $300m in sales from these facilities by 2028. Merck aims to focus on innovation-driven life sciences businesses, according to the company.

manufacturingchemist.com2 min
NOV 3
MedAI 9/10

Merck charts course out of CDMO business with Lonza sale

Merck KGaA is selling its CDMO business to Lonza for a mid-triple-digit million-euro amount, including five US facilities and 1,100 employees. The deal aims to sharpen Merck's life sciences focus and free up resources for other areas, including pharmaceuticals. Lonza expects the acquisition to add $300 million in annual revenue starting in 2028. The transaction is expected to close in mid-2027.

pharmaphorum.com2 min
NOV 3
MedAI 8/10

Lonza to acquire five US manufacturing sites from Merck KGaA

Lonza will acquire five US manufacturing sites from Merck KGaA for low- to mid-triple-digit millions of Swiss francs. The deal, expected to close in mid-2027, will expand Lonza's US presence and add 1,100 employees. The sites focus on various pharmaceutical technologies, with Lonza expecting them to contribute around SFr250m in sales by 2028. The acquisition aligns with Lonza's growth strategy, according to the company.

pharmaceutical-technology.com2 min